Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome

Author(s): Robert Busch, Andreas V. Hadjinicolaou, Frances C. Hall

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 10 , 2012

Become EABM
Become Reviewer

Abstract:

T cells are implicated in both local and systemic pathophysiology of primary Sjögren’s syndrome (PSS). Lymphocytic infiltrates in exocrine glands are dominated by CD4+ T cells, some contributing to ectopic lymphoid tissue, others, unusually, exhibiting cytotoxic potential. Cytokine secretion patterns are complex, with Th1 and Th17 components implicated in pathology. Circulating T cells exhibit phenotypes consistent with hyperactivation, cytokine imbalance, and homeostatic alterations; CD4 lymphopenia is recognized as a risk factor for developing lymphoma. Evidence of oligoclonal expansion is found locally and systemically. Functional alterations (e.g. cytokine secretion profile, migratory potential, target cell interactions) are less clearly defined. Attempts at T cell-targeted therapy of PSS have been limited, although therapy targeted at other arms of the immune response may also affect T cells. A better understanding of T-cell dysregulation in PSS is required in order to understand its contribution to disease, aid prognosis, and improve therapeutic interventions aimed at this aspect of the disease.

Keywords: Autoimmune disease, cytokines, cytotoxicity, homeostasis, pathophysiology, Sjogren’s syndrome, T-cell activation, T lymphocyte subset, systemic pathophysiology, ectopic lymphoid tissue, lymphoma, cytokine, aid prognosis, lymphocytes collaborate, tissue damage occurs.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 10
Year: 2012
Page: [2009 - 2021]
Pages: 13
DOI: 10.2174/138920112802273092
Price: $65

Article Metrics

PDF: 16